Kaplan-Meier survival plot of MET-1 tumor-bearing SCID/NOD mice in the small-tumor–burden therapeutic study.

At the time of the experiment, the mice had sIL-2Rα levels of 1000 to 10 000 pg/mL. Mice in the control group did not receive any treatment. Mice in the HAT group received 100 μg HAT once per week for 4 weeks. Mice in the PRIT group received 140 μg HAT-SA pretargeting for 24 hours, 100 μg sCA for 4 hours, and 0.3 μg²¹³Bi–DOTA-biotin at a dose of 250 μCi (9.25 MBq). Mice in the PRIT (nonspecific, ns) group received 140 μg B3-SA pretargeting for 24 hours, 100 μg sCA for 4 hours, and 0.3 μg²¹³Bi–DOTA-biotin at a dose of 250 μCi (9.25 MBq).